SP 2 0 2007

Attorney Docket No.: 5655.204-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pedersen et al.

Confirmation No: 7651

Serial No.: 09/390,851

Group Art Unit: 1627

Filed: September 7, 1999

Examiner: Prasthoffer, T.

For: Enzyme Activity Screen With Direct Substrate Reloading

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

**Box: Restrict** 

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)

2. Preliminary Amendment and Response to Restriction Requirement

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box: Restrict

Commissioner for Patents Washington, DC 20231

on September 17, 2001.

Kelley O'Patry

(name of person mailing paper)

(signature of person mailing paper)



ttorney Docket No.: 5655.204-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pedersen et al.

Confirmation No: 7651

Serial No.: 09/390,851

Group Art Unit: 1627

Filed: September 7, 1999

Examiner: Prasthoffer, T.

For: Enzyme Activity Screen With Direct Substrate Reloading

## AMENDMENT FEE TRANSMITTAL

Commissioner for Patents Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed July 19, 2001.

It is respectfully requested that the time for response to the Office Action dated July 19, 2001 be extended for a period of 1 month from August 19, 2001 to September 19, 2001. The required fee for the extension is estimated to be \$110.00.

The fee for claims has been calculated as shown below:

Total:  $28 - 27 = 1 \times 18 = $18$ 

Independent:  $1 - 3 = 0 \times 80 = $0$ 

Total additional fee for claims required is \$18.

Please charge the required extension and claims fees, estimated to be \$128, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: September 17, 2001

Jason I. Gafbell, Reg. No. 44,116 Novozymes North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123

09390851 09/21/2001 MWOLDER1 00000086 501701

01 FC:115

110.00 CH

09/21/2001 NWOLDER1 00000086 501701 09390851

02 FC:103

18.00 CH